Andy Pasternak's Insider Trades & SAST Disclosures
Andy Pasternak's most recent trade in Context Therapeutics Inc was a trade of 20,685 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Andy Pasternak.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Context Therapeutics Inc | Andy Pasternak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2025 | 20,685 | 20,685 | - | - | Stock Option (right to buy) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 113.03 per share. | 17 Jan 2023 | 27,129 | 56,338 (0%) | 0% | 113.0 | 3,066,323 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2023 | 22,997 | 22,997 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 88,733 | 122,780 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.80 per share. | 30 Dec 2022 | 39,313 | 83,467 (0%) | 0% | 113.8 | 4,473,819 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 26,124 | 0 | - | - | Performance Restricted Stock Units (PSU) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 14,514 | 0 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 11,648 | 5,816 | - | - | Performance Restricted Stock Units (PSU) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 11,643 | 11,643 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 8,709 | 0 | - | - | Performance Restricted Stock Units (PSU) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 7,935 | 15,870 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 5,800 | 0 | - | - | Performance Restricted Stock Units (PSU) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 2,360 | 0 | - | - | Performance Restricted Stock Units (PSU) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 26,124 | 26,124 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 17,464 | 17,464 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 112.61 per share. | 13 Dec 2022 | 23,251 | 40,965 (0%) | 0% | 112.6 | 2,618,207 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2022 | 23,251 | 0 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.52 per share. | 13 Dec 2022 | 23,251 | 64,216 (0%) | 0% | 29.5 | 686,370 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP, Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 112.60 per share. | 13 Dec 2022 | 6,918 | 34,047 (0%) | 0% | 112.6 | 778,965 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2022 | 12,421 | 0 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2022 | 12,421 | 46,468 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.18 per share. | 01 Nov 2022 | 5,503 | 40,965 (0%) | 0% | 63.2 | 347,680 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 82.44 per share. | 29 Jul 2022 | 4,207 | 34,690 (0%) | 0% | 82.4 | 346,825 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 83.45 per share. | 29 Jul 2022 | 643 | 34,047 (0%) | 0% | 83.4 | 53,658 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 85.36 per share. | 10 Jun 2022 | 762 | 38,897 (0%) | 0% | 85.4 | 65,044 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 94.82 per share. | 18 Feb 2022 | 1,313 | 39,659 (0%) | 0% | 94.8 | 124,499 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 48,839 | 70,669 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2022 | 23,805 | 23,805 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.84 per share. | 04 Jan 2022 | 21,710 | 48,959 (0%) | 0% | 101.8 | 2,210,946 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 14,514 | 14,514 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 11,642 | 23,286 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 11,616 | 5,800 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 11,067 | 11,069 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 99.85 per share. | 04 Jan 2022 | 6,438 | 41,321 (0%) | 0% | 99.8 | 642,834 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 98.33 per share. | 04 Jan 2022 | 700 | 47,759 (0%) | 0% | 98.3 | 68,831 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 97.30 per share. | 04 Jan 2022 | 500 | 48,459 (0%) | 0% | 97.3 | 48,650 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 100.23 per share. | 04 Jan 2022 | 349 | 40,972 (0%) | 0% | 100.2 | 34,980 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 07 Dec 2021 | 1,525 | 21,830 (0%) | 0% | 100 | 152,500 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2021 | 23,251 | 23,251 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.52 per share. | 04 Nov 2021 | 23,251 | 53,523 (0%) | 0% | 29.5 | 686,370 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 115.51 per share. | 04 Nov 2021 | 7,264 | 23,355 (0%) | 0% | 115.5 | 839,065 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 111.47 per share. | 04 Nov 2021 | 6,336 | 41,703 (0%) | 0% | 111.5 | 706,274 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 113.54 per share. | 04 Nov 2021 | 5,650 | 33,347 (0%) | 0% | 113.5 | 641,501 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 110.64 per share. | 04 Nov 2021 | 5,484 | 48,039 (0%) | 0% | 110.6 | 606,750 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 114.49 per share. | 04 Nov 2021 | 2,728 | 30,619 (0%) | 0% | 114.5 | 312,329 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 112.44 per share. | 04 Nov 2021 | 2,706 | 38,997 (0%) | 0% | 112.4 | 304,263 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 12,421 | 35,775 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 12,421 | 12,421 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 118.29 per share. | 01 Nov 2021 | 5,503 | 30,272 (0%) | 0% | 118.3 | 650,950 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2021 | 23,250 | 46,502 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.52 per share. | 09 Sep 2021 | 23,250 | 46,604 (0%) | 0% | 29.5 | 686,340 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 107.83 per share. | 09 Sep 2021 | 22,754 | 23,850 (0%) | 0% | 107.8 | 2,453,564 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 108.26 per share. | 09 Sep 2021 | 496 | 23,354 (0%) | 0% | 108.3 | 53,697 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2021 | 17,418 | 17,418 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2021 | 8,708 | 27,212 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 102.50 per share. | 28 Jul 2021 | 3,858 | 23,354 (0%) | 0% | 102.5 | 395,445 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 17,416 | 17,416 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 4,718 | 4,718 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 2,358 | 18,787 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.17 per share. | 17 Feb 2021 | 1,045 | 17,742 (0%) | 0% | 87.2 | 91,093 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 34,928 | 34,928 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 Jan 2021 | 14,513 | 29,028 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 14,513 | 22,955 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.28 per share. | 04 Jan 2021 | 6,526 | 16,429 (0%) | 0% | 73.3 | 478,225 | Ordinary Shares |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2020 | 12,420 | 24,842 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2020 | 12,420 | 13,945 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Andy Pasternak | EVP and Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.93 per share. | 01 Nov 2020 | 5,503 | 8,442 (0%) | 0% | 74.9 | 412,340 | Ordinary Shares |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges